Lactobacillus as Anti-Biofilm Therapeutics: Formulation and Delivery Challenges in Clinical Translation
DOI:
https://doi.org/10.63682/jns.v14i32S.8219Keywords:
Lactobacillus, biofilm, antimicrobial resistance, live biotherapeutic products, encapsulation, CRISPR, probiotic delivery, regulatory challenges, microbial therapeuticsAbstract
Background: Biofilm-associated infections contribute to nearly 65% of all microbial infections and are notoriously resistant to conventional antibiotics. The protective extracellular polymeric matrix and metabolic heterogeneity of biofilms make treatment particularly challenging. Lactobacillus species have emerged as promising anti-biofilm agents due to their ability to produce antimicrobial compounds, disrupt biofilm architecture, and enhance host immune responses. However, their clinical application remains limited by significant formulation and delivery barriers. The objective of the review is to critically evaluate the anti-biofilm potential of Lactobacillus, identify the key challenges hindering its clinical translation, and explore technological and regulatory strategies to overcome these limitations.
Methods: This review integrates current literature on the antimicrobial mechanisms of Lactobacillus, assesses the environmental and physiological stressors impacting therapeutic viability, and analyzes recent advances in protective formulation technologies, genetic engineering, and synergistic therapies. The review also examines the regulatory landscape governing Live Biotherapeutic Products (LBPs).
Results: Lactobacillus exerts multi-modal anti-biofilm effects through the production of organic acids, bacteriocins, biosurfactants, and hydrogen peroxide, alongside competitive exclusion and immunomodulation. However, survival is severely compromised by manufacturing stress, gastric acidity, bile exposure, oxidative damage, and microbiota competition. Technological innovations such as microencapsulation, enteric coatings, biofilm-based delivery platforms, and CRISPR-based strain enhancements significantly improve viability and efficacy. Combination therapies with bacteriophages and matrix-degrading enzymes offer synergistic benefits. Nonetheless, the regulatory framework for LBPs demands extensive characterization, safety assurance, and novel clinical trial designs, presenting additional hurdles.
Conclusion: Lactobacillus-based therapeutics offer a promising solution for biofilm-related infections, but successful clinical translation demands integrated advances in formulation, genetic engineering, regulation, and personalized strategies—driven by interdisciplinary collaboration
Downloads
Metrics
References
Mgomi FC, Yang YR, Cheng G, Yang ZQ. Lactic acid bacteria biofilms and their antimicrobial potential against pathogenic microorganisms. Biofilm. 2023;5:100118. doi: 10.1016/j.bioflm.2023.100118. PMID: 37125395; PMCID: PMC10139968.
Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol. 2002;292(2):107-13. doi: 10.1078/1438-4221-00196. PMID: 12195733.
Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276-301. doi: 10.1093/femsre/fux010. PMID: 28369412.
Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322-32. doi: 10.1016/j.ijantimicag.2009.12.011. PMID: 20149602.
Anjana, Tiwari SK. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Front Cell Infect Microbiol. 2022;12:851140. doi: 10.3389/fcimb.2022.851140. PMID: 35651753; PMCID: PMC9149203.
Umu ÖC, Bäuerl C, Oostindjer M, Pope PB, Hernández PE, Pérez-Martínez G, Diep DB. The potential of class II bacteriocins to modify gut microbiota to improve host health. PLoS One. 2016;11(10):e0164036. doi: 10.1371/journal.pone.0164036. PMID: 27695121; PMCID: PMC5047468.
Duarte AC, Almeida SF, Coimbra J, Lecerf M, Ressier L, Freitas R, Bento L. Use of potential probiotic lactic acid bacteria (LAB) biofilms for the control of Listeria monocytogenes, Salmonella Typhimurium, and Escherichia coli biofilms formation. Front Microbiol. 2016;7:863. doi: 10.3389/fmicb.2016.00863. PMID: 27375580; PMCID: PMC4894990.
Tahmourespour A, Salehi R, Kermanshahi RK, Eslami G. The anti-biofouling effect of Lactobacillus fermentum-derived biosurfactant against Streptococcus mutans. Biofouling. 2011;27(4):385-398. doi: 10.1080/08927014.2011.57 5458. PMID: 21534041.
Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab. 2012;61(2):160-174. doi: 10.1159/000342079. PMID: 23037511.
Liu H, Cui SW, Chen M, Li Y, Liang R, Xu F, Zhong F. Protective approaches and mechanisms of microencapsulation to the survival of probiotic bacteria during processing, storage and gastrointestinal digestion: a review. Crit Rev Food Sci Nutr. 2019;59(17):2863-2878. doi: 10.1080/10408398.2017.1377684. PMID: 28933562.
Binda S, Hill C, Johansen E, Obis D, Pot B, Sanders ME, Tremblay A, Ouwehand AC. Criteria to qualify microorganisms as "probiotic" in foods and dietary supplements. Front Microbiol. 2020;11:1662. doi: 10.3389/fmicb.2020.01662. PMID: 32760367; PMCID: PMC7371409.
Fenster K, Freeburg B, Hollard C, Wong C, Rønhave Laursen R, Ouwehand AC. The production and delivery of probiotics: a review of a practical approach. Microorganisms. 2019;7(3):83. doi: 10.3390/microorganisms7030083. PMID: 30893738; PMCID: PMC6463098.
Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Groeger D, Van Pijkeren JP, Reid G. Live biotherapeutic products, a road map for safety assessment. Front Med (Lausanne). 2020;7:237. doi: 10.3389/fmed.2020.00237. PMID: 32671077; PMCID: PMC7319051.
Pot B, Vandenplas Y. Factors that influence clinical efficacy of live biotherapeutic products. Eur J Med Res. 2021;26(1):40. doi: 10.1186/s40001-021-00509-7. PMID: 33849599; PMCID: PMC8042840.
Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RB, Federici S, Horn M, Cohen Y, Moor AE, Zeevi D, Korem T, Kotler E, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Pevsner-Fischer M, Shapiro H, Sharon I, Halpern Z, Segal E, Elinav E. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388-1405.e21. doi: 10.1016/j.cell.2018.08.041. PMID: 30193112.
Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012;162(1):56-67. doi: 10.1016/j.jconrel.2012.06.003. PMID: 22698940.
Liu L, Liu L, Guo S, Tang C, Zhou Y, Zhang J, Zhang Y. Biofilm-based delivery approaches and specific enrichment strategies of probiotics in the human gut. Gut Microbes. 2022;14(1):2126274. doi: 10.1080/19490976.2022.2126274. PMID: 36227838; PMCID: PMC9578482.
Hidalgo-Cantabrana C, O'Flaherty S, Barrangou R. CRISPR-based engineering of next-generation lactic acid bacteria. Curr Opin Microbiol. 2017;37:79-87. doi: 10.1016/j.mib.2017.05.015. PMID: 28618305.
Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumarasamy M, Norris JS, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Proehl F, Krummenacher C, Schriefer I, Burrowes B, Torres C, Large K, Dalai SC, Alaswad Z, Kebriaei R, Burgess LD, Kaushik A, Chen L, Kreiswirth BN, Chauhan A, Leung SS, Nazarian EJ, Townsend ML, Ostrowsky BE, Tomas M, Nigo M, Aslam S, Kaye KS, Patel R, Kaye KS. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954-17. doi: 10.1128/AAC.00954-17. PMID: 28807909; PMCID: PMC5610519.
Ahmad MF, Aman F, Arif MS, Ahmad FA. Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med. 2020;52(9):1397-1406. doi: 10.1038/s12276-020-0437-6. PMID: 32908212; PMCID: PMC8080583.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
